Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Выявить: исследование фазы 3 Ion582 в синдроме Ангелмана

28 сентября 2026 г. обновлено: Ionis Pharmaceuticals, Inc.

Фаза 3 Изучение эффективности и безопасности ION582 у детей и взрослых с синдромом Ангелмана

The purpose of this study is to evaluate the efficacy and safety of obudanersen in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.

Обзор исследования

Статус

Активный, не рекрутирующий

Подробное описание

This is a Phase 3, randomized, double-blind, placebo-controlled study in people with Angelman syndrome. The study will consist of 4 periods: a screening period of up to 28 days, an approximate 60-week double blind, placebo-controlled treatment period, followed by an approximate 25-month Long-Term Extension (LTE) treatment period, and an approximate 8-month Post-LTE follow-up period. The study will be comprised of 2 cohorts. Cohort 1 will include pediatric participants, aged 2 to less than (<)18 years old and serve as the population for evaluation of primary and secondary outcome measures; Cohort 2 will include adult participants, aged 18 to ≤50 years old. Participants will be randomized 1:1 to 80 mg obudanersen or placebo during the double-blind placebo-controlled treatment period. Participants from both cohorts completing the placebo-controlled treatment period will be eligible to transition into the LTE Treatment Period wherein all trial participants will receive obudanersen. Participant, Caregiver, Investigator and Sponsor will remain blinded to the obudanersen dose administered to participants during the LTE.

The study initiated in 2024 with three dosing groups (40 mg obudanersen, 80 mg obudanersen, and placebo). Following additional review of data from the ongoing Phase 1/2 trial of obudanersen (HALOS), REVEAL was amended in December 2025 to its current form as a two-arm study: 80 mg obudanersen and placebo. Following the amendment, participants who were randomized to receive 40 mg obudanersen will be transitioned to receive 80 mg obudanersen.

Тип исследования

Интервенционный

Регистрация (Действительный)

156

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Heidelberg, Австралия, 3084
        • Austin Hospital
      • Nedlands, Австралия, 6009
        • Perth Children's Hospital
      • Randwick, Австралия, 2031
        • Sydney Children's Hospital
    • Queensland
      • South Brisbane, Queensland, Австралия, 4101
        • Queensland Children's Hospital
      • München, Германия, 81377
        • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
      • Ramat Gan, Израиль, 5265601
        • Sheba Medical Center
      • Barcelona, Испания, 08950
        • Hospital Sant Joan de Deu
      • Sabadell, Испания, 08208
        • Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
      • Milan, Италия, 20133
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
      • Pisa, Италия, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Roma, Италия, 00165
        • Ospedale Pediatrico Bambino Gesù
      • Edmonton, Канада, T6G 2B7
        • University of Alberta Hospital
      • Vancouver, Канада, V6H 3V4
        • British Columbia Children's Hospital
    • Ontario
      • London, Ontario, Канада, N6A 5W9
        • London Health Science Centre - Children's Hospital
    • Quebec
      • Montreal, Quebec, Канада, H4A 3J1
        • McGill University Health Centre
      • Gdansk, Польша, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Singapore, Сингапур, 229899
        • KK Women's and Children's Hospital
      • London, Соединенное Королевство, WC1N 3JH
        • Great Ormond Street Hospital for Children - NHS Foundation Trust
      • Oxford, Соединенное Королевство, OX3 9DU
        • John Radcliffe Hospital
    • California
      • Los Angeles, California, Соединенные Штаты, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Соединенные Штаты, 90095
        • UCLA Clinical & Translational Research Center (CTRC)
      • San Diego, California, Соединенные Штаты, 92123
        • Rady Children's Hospital
    • Colorado
      • Aurora, Colorado, Соединенные Штаты, 80045
        • Colorado Children's Hospital Research Institute
    • District of Columbia
      • Washington D.C., District of Columbia, Соединенные Штаты, 20011
        • Children's National Hospital
    • Florida
      • Miami, Florida, Соединенные Штаты, 33155
        • Nicklaus Children's Hospital
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30329
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60612
        • Rush University Medical Center
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, Соединенные Штаты, 64108
        • Children's Mercy
    • New York
      • New York, New York, Соединенные Штаты, 10032
        • Columbia University Irving Medical Center
      • New York, New York, Соединенные Штаты, 10029
        • Ichan School of Medicine at Mount Sinai
    • North Carolina
      • Carrboro, North Carolina, Соединенные Штаты, 27510
        • University of North Carolina at Chapel Hill School of Medicine
    • Ohio
      • Cincinnati, Ohio, Соединенные Штаты, 45229
        • Cincinnati Children's Hospital
      • Columbus, Ohio, Соединенные Штаты, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Соединенные Штаты, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Nashville, Tennessee, Соединенные Штаты, 37232
        • Vanderbilt Clinical Research Center
    • Texas
      • Houston, Texas, Соединенные Штаты, 77030
        • Texas Children's Hospital
      • Seoul, Южная Корея, 03080
        • Seoul National University Hospital
      • Seoul, Южная Корея, 06351
        • Samsung Medical Center
    • Osaka
      • Izumi, Osaka, Япония, 594-1101
        • Osaka Women's and Children's Hospital
    • Tokyo
      • Kodaira, Tokyo, Япония, 187-8551
        • National Center of Neurology and Psychiatry

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 2 года до 50 лет (Ребенок, Взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Key Inclusion Criteria:

  1. The participants caregiver(s)/ legally authorized representative must have given written informed consent and any authorizations required by local law and be able to comply with all study requirements.
  2. Medically stable and can undergo sedation and/or general anesthesia without intubation.
  3. Male or female between 2 and lesser than or equal to (≤)50 years of age, depending on specific cohort, at the time of the in-clinic Screening visit.
  4. Participant has a clinical diagnosis of Angelman syndrome (AS) with molecular confirmation of either Ubiquitin-protein ligase E3A (UBE3A) deletion or UBE3A mutation.
  5. Currently receiving stable doses of concomitant medications typically prescribed for AS, such as anti-epileptic medication, behavioral management medications, sleep medications, gabapentin, cannabidiol, and special diets, supplements, or nutritional support for at least 8 weeks prior to the Baseline visit.
  6. Legally authorized representative/caregiver(s) agree(s) not to post any of the participant's personal medical data or information related to the study on any website or social media site (e.g., Facebook, Instagram, X (formerly Twitter), YouTube, TikTok, etc.) from the time of enrollment until they are notified that the study is completed.

Key Exclusion Criteria:

  1. Must not have any clinically significant abnormalities in medical history (e.g., major surgery within 3 months of screening), or on physical examination for which treatment with an antisense oligonucleotide (ASO) would be contraindicated or which, in the opinion of the Principal Investigator (PI), could confound the results of this study.
  2. Known brain or spinal disease that would interfere with the lumbar puncture (LP) procedure, cerebrospinal fluid (CSF) circulation, or presence of other factors would affect the safety of the LP procedure.
  3. Must not have any other conditions, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.
  4. Must not have any laboratory abnormalities or any other clinically significant abnormalities that would, as assessed by the Investigator, at screening or Baseline, render a participant unsuitable for inclusion.
  5. Previous treatment with an oligonucleotide (including small interfering ribonucleic acid (RNA) [siRNA], ASOs) gene therapy or gene editing. This exclusion criterion does not apply to approved nucleic acid-based vaccines, including mRNA vaccines, which are allowed.
  6. Has molecular confirmation of AS due to paternal uniparental disomy, imprinting center defect, or mosaic findings.

Other inclusion/exclusion criteria may apply.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Cohort 1 obudanersen 80 mg

Participants (aged 2 to <18 years old) will be administered obudanersen 80 mg via intrathecal (IT) injection every 12 weeks during the double blind and LTE treatment periods.

obudanersen will be administered by IT injection.

Другие имена:
  • ION582
Плацебо Компаратор: Cohort 1 Placebo

Participants (aged 2 to <18 years old) will be administered obudanersen matching placebo via IT injection every 12 weeks during the double-blind treatment period and then administered obudanersen 40 mg or 80 mg every 12 weeks during the LTE treatment period.

obudanersen matching placebo will be administered by IT injection.

Экспериментальный: Cohort 2 obudanersen 80 mg

Participants (aged 18 to ≤50 years old) will be administered obudanersen 80 mg via IT injection every 12 weeks during the double blind and LTE treatment periods.

obudanersen will be administered by IT injection.

Другие имена:
  • ION582
Плацебо Компаратор: Cohort 2 Placebo

Participants (aged 18 to ≤50 years old) will be administered obudanersen matching placebo via IT injection every 12 weeks during the double-blind treatment period and then randomized to obudanersen 40 mg or 80 mg every 12 weeks during the LTE treatment period.

obudanersen matching placebo will be administered by IT injection.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1
Временное ограничение: Baseline and Week 52

The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The expressive communication subdomain of communication measures preverbal and verbal communication. The total raw score reflects the sum of all the item scores within the expressive communication subdomain, with higher scores reflecting greater expressive communication ability.

Baseline and Week 52

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Процент участников с нежелательными явлениями с лечением (TEAE) и серьезными побочными эффектами (SAE)
Временное ограничение: До 52 недели
До 52 недели
Изменение жизненно важных признаков и результатов клинических лабораторий
Временное ограничение: Базовая линия и неделя 52
Базовая линия и неделя 52
Change in Bayley Scales for Infant and Toddler Development-4 (Bayley-4): Cognition Subdomain Raw Score Without Caregiver Input
Временное ограничение: Baseline and Week 52

The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The cognitive subdomain measures learning, memory and concept formation. The total raw score reflects the sum of all the item scores within the expressive communication subdomain, with higher scores reflecting greater cognitive ability.

Baseline and Week 52
Change in Symptoms of Angelman Syndrome -Clinician Global Impression of Change (SAS-CGI-C): Overall AS
Временное ограничение: Baseline and Week 52

The SAS-CGI-C for Overall AS is a disease-specific clinician-reported outcome assessment measure for Angelman syndrome. The clinicians rate their overall impression of the change of the participant's Angelman syndrome symptoms utilizing a 7-point scale, ranging from "very much improved" (1) to "very much worse" (7).

Baseline and Week 52
Change in Vineland Adaptive Behavior Scale-3 (Vineland-3): Receptive Communication Subdomain Raw Score
Временное ограничение: Baseline and Week 52

The Vineland-3 assesses adaptive behaviors across 4 domains via a semi-structured interview between a trained clinician and the caregiver of the participant with AS. The receptive communication subdomain of communication measures the participant's ability to attend, understand, and respond appropriately to information from others. The total raw score reflects the sum of all the item scores within the receptive communication subdomain, with higher scores reflecting greater receptive communication ability.

Baseline and Week 52
Change in Vineland Adaptive Behavior Scale-3 (Vineland-3): Daily Living Skills, Personal Subdomain Raw Score
Временное ограничение: Baseline and Week 52

The Vineland-3 assesses adaptive behaviors across 4 domains via a semi-structured interview between a trained clinician and the caregiver of the participant with AS. The Personal subdomain of the Daily Living Skills domain measures the participant's self-sufficiency in such areas as eating, dressing, washing, hygiene, and health care. The total raw score reflects the sum of all the item scores within the Personal subdomain, with higher scores reflecting greater ability.

Baseline and Week 52
Change in Symptoms of Angelman Syndrome - Clinician Global Impression of Change (SAS-CGI-C): Sleep Problems
Временное ограничение: Baseline and Week 52

The SAS-CGI-C for Sleep Problems is a disease-specific clinician-reported outcome assessment measure for Angelman syndrome. The clinicians rate their overall impression of the change in the participant's sleep problems utilizing a 7-point scale, ranging from "very much improved" (1) to "very much worse" (7).

Baseline and Week 52
Change in Bayley Scales for Infant and Toddler Development-4 (Bayley-4): Fine Motor Subdomain Raw Score Without Caregiver Input
Временное ограничение: Baseline to Week 52

The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The Fine Motor subdomain of communication measures motor abilities such as reaching, object manipulation, and grasping. The total raw score reflects the sum of all the item scores within the fine motor subdomain, with higher scores reflecting greater fine motor ability.

Baseline to Week 52
Change in Observer-Reported Communication Ability (ORCA): Overall Emerging T Score
Временное ограничение: Baseline and Week 52

The ORCA measure assesses, from the caregiver's perspective, the communication ability of individuals with neurodevelopmental disorders, like Angelman syndrome. This questionnaire assesses expressive, receptive, and pragmatic communication. The ORCA measure produces a single score that is an estimate of an individual's overall level of communication ability, with higher T-scores reflecting greater communication ability.

Baseline and Week 52

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

10 июня 2025 г.

Первичное завершение (Оцененный)

1 августа 2027 г.

Завершение исследования (Оцененный)

1 апреля 2030 г.

Даты регистрации исследования

Первый отправленный

22 марта 2025 г.

Впервые представлено, что соответствует критериям контроля качества

31 марта 2025 г.

Первый опубликованный (Действительный)

6 апреля 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

29 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

28 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться